SALSA MLPA P128 Cytochrome P-450 probemixbasic research

This SALSA® MLPA® kit is for basic research and intended for experienced MLPA users only! This kit enables you to quantify genes or chromosomal regions in which the occurrence or relevance of copy number changes is not yet well-established. Hence, it will not always provide you with clear cut answers, and interpretation of results can be very complicated.

application: Cytochrome P-450
region: CYP2D6, CYP2C9, CYP2C19, CYP1B1, CYP3A4, CYP3A5, CYP2E1, CYP1A1, CYP1A2, CYP2A6, CYP2B6, GSTP1, GSTT1 and GSTM1
[login for my products]
version: C1
sold since: 2015-04-01

item no. description price
P128-025R SALSA MLPA P128 Cytochrome P-450 probemix – 25 rxn € 237,00€ 189,60
P128-050R SALSA MLPA P128 Cytochrome P-450 probemix – 50 rxn € 474,00€ 379,20
P128-100R SALSA MLPA P128 Cytochrome P-450 probemix – 100 rxn € 948,00€ 758,40

MRC-Holland offers a 20% discount off the normal selling price for the above probemixes

EK1-FAM SALSA MLPA EK1 reagent kit – 100 rxn - FAM € 294,00
EK1-Cy5 SALSA MLPA EK1 reagent kit – 100 rxn - Cy5 € 294,00
EK5-FAM SALSA MLPA EK5 reagent kit – 500 rxn - FAM € 1355,00
EK5-Cy5 SALSA MLPA EK5 reagent kit – 500 rxn - Cy5 € 1355,00

Please note that both a probemix and reagent kit are needed to perform MLPA.

description
Cytochrome P450 enzymes are important in the biosynthesis and degradation of endogenous compounds such as steroids, lipids and vitamins. These enzymes reduce or alter the pharmacologic activity of many drugs and facilitate their elimination. Differences in drug metabolism in the intestine or liver between patients are major contributors to drug response, including adverse effects.

Glutathione transferases are a family of proteins that play an important role in detoxification by catalyzing the conjugation of many compounds with reduced glutathione.

This P128-C1 Cytochrome P450 probemix is intended for the detection of copy number changes of several Cytochrome P450 and Glutathione S-transferase genes. It contains probes for the CYP2D6, CYP2C9, CYP2C19, CYP1B1, CYP3A4, CYP3A5, CYP2E1, CYP1A1, CYP1A2, CYP2A6, CYP2B6, GSTP1, GSTT1 and GSTM1 genes. In the normal population several of these genes differ in copy number. For each gene at least two probes are present. In addition, 12 reference probes are included in this P128-C1 probemix, detecting several different autosomal chromosomal locations.

An outline of the literature on these genes can be found in the OMIM database:
http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim.

This P128-C1 probemix does not contain probes for point mutations in CYP2D6 or the other genes! It will therefore not be possible to detect all poor metabolizers with this product.

SALSA® MLPA® probemixes are designed to detect deletions/duplications of one or more sequences in the aforementioned genes in a DNA sample. Heterozygous deletions of recognition sequences should give a 35-50% reduced relative peak height of the amplification product of that probe. Note that a mutation or polymorphism (e.g. SNP) in the sequence detected by a probe can also cause a reduction in relative peak height, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, deletions and duplications detected by MLPA should always be confirmed by other methods. Not all deletions and duplications detected by MLPA will be pathogenic; users should always verify the latest scientific literature when interpreting their findings. We have no information on what percentage of defects in these genes is caused by deletions/duplications of complete exons. Finally, note that most defects in this gene are expected to be small (point) mutations which will not be detected by this SALSA® MLPA® test.

product history
version C1: Nine reference probes have been replaced and one CYP2D6 probe has been removed.
version B2: QDX2 have been added
version B1: XY fragments, 2 CYP2C9 probes have been added. CYP2C19 and several reference probes have been replaced.
version A1: changes not specified

improved products
P294-Tumour Loss
Tumour Loss
P241-MODY Mix 1
Maturity-Onset Diabetes of the Young (MODY)
Newsletter  |  Home  |  Site map  |  Terms and Conditions  |  Search  |  Copyright © 2018 MRC-Holland